2020
Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC).
Bedke J, Merseburger A, Loriot Y, Castellano D, Choy E, Duran I, Rosenberg J, Petrylak D, Dreicer R, Perez-Gracia J, Hoffman-Censits J, Van Der Heijden M, Degaonkar V, Thiebach L, de Ducla S, Fear S, Powles T, Sternberg C. Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC). Journal Of Clinical Oncology 2020, 38: 492-492. DOI: 10.1200/jco.2020.38.6_suppl.492.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaStable diseasePartial responseDisease controlBaseline characteristicsRisk factorsPR/stable diseaseOverall survival durationProspective clinical trialsBroader patient populationAnalysis of outcomesData cutoffUnacceptable toxicityWorse OSComplete responseClinical outcomesMedian timeAnalysis populationPatient populationUrothelial carcinomaSurvival durationClinical trialsCohort 2Disease progressionResponse status
2016
The impact of androgen deprivation and pelvic radiation on the development of bladder cancer.
Hafez N, Wang R, Hurwitz M, Ma X, Petrylak D. The impact of androgen deprivation and pelvic radiation on the development of bladder cancer. Journal Of Clinical Oncology 2016, 34: 439-439. DOI: 10.1200/jco.2016.34.2_suppl.439.Peer-Reviewed Original ResearchAndrogen deprivation therapyUrothelial bladder cancerProstate cancer patientsSecondary bladder cancerBladder cancerCancer patientsRadiation therapyAndrogen deprivationProstate cancerRecurrent urothelial bladder cancerElderly prostate cancer patientsCox proportional modelingRetrospective cohort studyKaplan-Meier analysisSEER-Medicare databaseSimilar patient populationsProstate cancer treatmentPrimary prostate cancerDeprivation therapyMedian followPelvic radiationCohort studyMale predilectionProportional modelingPatient population